Topically applied drugs often follow different requirements for pharmacokinetic (PK) assessment than drugs administered orally or intravenously.
This webinar covers an introduction to topical drug development and important considerations for clinical pharmacology aspects for products for dermatological conditions. During the webinar, issues specific for topical drug development will be discussed including requirements, such as the maximal usage trial (MuST) for a successful application. At the end of this webinar attendees should have a better understanding of:
- Why does formulation matter?
- How to collect and interpret pharmacokinetics for topically applied products
- Regulatory requirements and clinical pharmacology considerations
Meet the Speaker
Elizabeth (Betty) Hussey, Pharm.D.
Vice President, Clinical Pharmacology & Pharmacokinetics
Dr. Hussey has over 30 years of extensive leadership and experience in drug development, clinical development, clinical pharmacology, and pharmacokinetics across multiple therapeutic areas and all phases of development. Dr. Hussey’s primary therapeutic area experience includes dermatology, metabolic diseases, CNS (headaches), antivirals, and anti-infectives with focus on early proof-of-concept.